The Australian Experience With the Human Papillomavirus Vaccine

摘要: Abstract Objective The goal of this study was to review the current human papillomavirus (HPV) vaccine program and its outcomes date in Australia. Methods This a published data relating introduction subsequent measurable quadrivalent vaccine, which became part Australian national HPV immunization 2007. Australia commenced an ongoing, schoolbased, government-funded, vaccination using from April 2007 for adolescent female subjects aged 12 13 years, together with catch-up 26 years age July December 31, 2009. Results community (lay clinical) have embraced program, resulting high coverage >70% 3 doses 12- 13-year-old ongoing target population. Vaccine effectiveness (outcomes real-world setting) is already being seen. has been noted significant reductions vaccine–related infections eligible (77% fall prevalence), rapid reduction >90% genital warts (first marker disease reduction, as well herd immunity), high-grade cervical lesions group. These remarkable changes so soon after implementation country occurred faster, greater extent, than anyone could predicted. Conclusions findings should encourage other countries follow suit, ultimate aim translating treatment into HPV-related neoplasia globally. greatest success such approach will only be realized when prophylactic vaccines are rolled out effectively, at affordable costs, those areas world highest burden disease. To achieve outcome requires government endorsement commitment; education large; realization safety, efficacy, immunogenicity available reducing disease, especially neoplasia; governments procuring prices through various options now (eg, support GAVI Alliance countries, tiered pricing, negotiation pharmaceutical manufacturers). We tools reach goal, it time these were implemented.